
Bringing Biologics Medical Innovation to International Markets
About Us
KGbio is a clinical-stage biotechnology company focused on bringing biologics medical innovation to markets outside the US/Canada, Western Europe and China. The business model revolves around in-licensing novel biologics and select biosimilars in oncology and high-specialty therapeutic areas (typically pre-IND or early clinical stage), with the objective to out-license them in target geographies after finishing clinical development as well as regulatory and reimbursement approvals. Platforms of interest currently include Fc-fusion proteins, antibodies, bispecifics, ADCs, cell therapies and therapeutic vaccines. The company is backed by Asian pharma companies Kalbe (market cap US$5.5 billion) and Genexine (market cap US$1.3 billion) and US private equity giant General Atlantic (AUM US$ 78 billion)
Business Lines

Geographic Focus

Business Model and Value Proposition

The Opportunity


Management Team

Board Members and Current Investors


Pipeline


Platforms of Interest

Manufacturing

Contract Manufacturing Clientele

GET IN TOUCH
Kalbe building 3rd floor. Jl. Letjend Suprapto Kav 4, Jakarta 10510, Indonesia
(6221) 42873888